Raymond James Financial’s Capricor Therapeutics CAPR Stock Holding History

Raymond James Financial’s Portfolio CAPR Stock Details CAPR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$4.74M	Buy	196,856 +556	+0.3%	+$16.9K	﹤0.01%	2773
2026 Q1	$5.97M	Buy	196,300 +910	+0.5%	+$24.2K	﹤0.01%	2454
2025 Q4	$5.64M	Buy	195,390 +4,098	+2%	+$53.5K	﹤0.01%	2424
2025 Q3	$1.38M	Buy	191,292 +180,234	+1,630%	+$1.33M	﹤0.01%	3461
2025 Q2	$110K	Sell	11,058 -58	-0.5%	-$613	﹤0.01%	4830
2025 Q1	$105K	Buy	+11,116	New	+$154K	﹤0.01%	4539

Other funds holding CAPR

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

TCM

Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return

SCM

Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

BCM

Boxer Capital Management San Diego, California $1.33B AUM 864.5% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Raymond James Financial's CAPR Position: Q2 2026 in Review

Raymond James Financial increased its Capricor Therapeutics (CAPR) stake by 0.28% in Q2 2026, buying an estimated $16.9K and bringing the position to 196,856 shares worth $4.74M. The position accounts for ﹤0.01% of the portfolio, ranked #2773.

Raymond James Financial first reported a position in CAPR in Q1 2025 and has held it in 6 quarters since. The position peaked at $5.97M in Q1 2026. 169 funds tracked by Wall St. Rank hold CAPR as of Q2 2026.

Raymond James Financial held 196,856 shares of Capricor Therapeutics worth $4.74M as of Q2 2026.
Raymond James Financial bought 556 Capricor Therapeutics shares in Q2 2026, an estimated $16.9K.
Capricor Therapeutics made up ﹤0.01% of Raymond James Financial's portfolio in Q2 2026, its #2773 holding.
Raymond James Financial first reported a position in Capricor Therapeutics in Q1 2025 and has held it in 6 quarters since.
Raymond James Financial's Capricor Therapeutics position peaked at $5.97M in Q1 2026.
169 funds tracked by Wall St. Rank held Capricor Therapeutics as of Q2 2026.

Based on Raymond James Financial's 13F filing for Q2 2026, filed 14 Aug 2026.